Novo Nordisk A S (NVO) Stock Forecast Oct. 16, 2026

Our AI ranks Novo Nordisk A S outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Novo Nordisk A S is a large-cap company with a market capitalization of $172.56B. It ranks number 8 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its ROE of 176.6% is the highest of the 38 peers that report one. Its Current Ratio of 0.80x is the lowest of the 59 peers that report one.

For NVO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 3.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -3.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)

All daily signals →